Unveiling expanded indications for prophylactic vaccines, anticancer vaccines, and rare disease therapies
[by Yu, Suin] GC Biopharma announced on November 26 that it has recently disclosed key research findings on its ‘next-generation mRNA-LNP platform for innovative drug development’ at both domestic and international academic conferences.
In its messenger ribonucleic acid (mRNA) platform research, GC Biopharma markedly enhanced both the level and durability of mRNA-driven protein expression by leveraging its proprietary UTR-related patents and AI-supported codon optimization technology. In parallel, the company’s lipid nanoparticle (LNP) delivery platform exhibited improved cell-specific delivery efficiency while maintaining low toxicity profiles.
GC Biopharma is advancing the development of multiple novel drug candidates based on this mRNA-LNP platform. The company is currently exploring the platform’s applicability not only to vaccines for infectious diseases, including COVID-19 and influenza, but also to oncologic vaccines, rare disease therapeutics, gene-editing approaches, and cellular immunotherapies such as chimeric antigen receptor T-cell (CAR-T)-based treatment modalities.
In particular, 바카라 카드카운팅 Biopharma's anticancer vaccine research, leveraging its proprietary LNP delivery system, elicited a more potent antigen-specific CD8+ T cell response compared with the benchmark LNP and significantly reduced tumor size in preclinical animal models. CD8+ T cells are key immune cells that kill malignant cancer cells.
Furthermore, the CAR-T cell therapy candidate developed using its proprietary 바카라 카드카운팅 technology demonstrated strong ex vivo testing results, eliminating up to 99% of B cells. B cell elimination is a widely recognized functional indicator of CAR-T antitumor efficacy, as the capacity to remove aberrant or malignant B cells directly correlates with therapeutic performance. The company also announced its intention to broaden clinical development to include oncologic indications and autoimmune disease applications.
"The mRNA-LNP platform is evolving beyond vaccines and expanding into multiple therapeutic areas. GC Biopharma will continue to develop innovative therapeutics, building on the research achievements accumulated to date," said Ma Sung-hoon, Head of Medicine Discovery & Development at GC Biopharma.
Conversely, 바카라 카드카운팅 Biopharma participated in and delivered scientific presentations at the 2025 Korean Society for Gene and Cell Therapy (KS바카라 카드카운팅T) regular academic conference, the 2025 mRNA Healthcare Conference, and the RNA-based Therapeutics and Vaccines Summit Asia throughout November.